ZA200500768B - Crystal forms os quinoxaline-2-carboxylic acid Ä4-carbomoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-,ethyl-octylÜ-amide - Google Patents

Crystal forms os quinoxaline-2-carboxylic acid Ä4-carbomoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-,ethyl-octylÜ-amide

Info

Publication number
ZA200500768B
ZA200500768B ZA200500768A ZA200500768A ZA200500768B ZA 200500768 B ZA200500768 B ZA 200500768B ZA 200500768 A ZA200500768 A ZA 200500768A ZA 200500768 A ZA200500768 A ZA 200500768A ZA 200500768 B ZA200500768 B ZA 200500768B
Authority
ZA
South Africa
Prior art keywords
octylü
carbomoyl
fluorobenzyl
quinoxaline
dihydroxy
Prior art date
Application number
ZA200500768A
Other languages
English (en)
Inventor
John C Kath
Zheng J Li
Zhengong Li
Eric B Mcelroy
Clifford N Meltz
Christopher S Poss
Original Assignee
Pfizer Produtcs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Produtcs Inc filed Critical Pfizer Produtcs Inc
Publication of ZA200500768B publication Critical patent/ZA200500768B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200500768A 2002-08-12 2005-01-26 Crystal forms os quinoxaline-2-carboxylic acid Ä4-carbomoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-,ethyl-octylÜ-amide ZA200500768B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
ZA200500768B true ZA200500768B (en) 2006-07-26

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500768A ZA200500768B (en) 2002-08-12 2005-01-26 Crystal forms os quinoxaline-2-carboxylic acid Ä4-carbomoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-,ethyl-octylÜ-amide

Country Status (22)

Country Link
US (1) US20040072834A1 (pt)
EP (1) EP1539715A1 (pt)
JP (1) JP2005538130A (pt)
AP (1) AP2005003226A0 (pt)
AR (1) AR040839A1 (pt)
AU (1) AU2003250450A1 (pt)
BR (1) BR0313378A (pt)
CA (1) CA2494776A1 (pt)
EC (1) ECSP055588A (pt)
GT (1) GT200300169A (pt)
IL (1) IL166548A0 (pt)
IS (1) IS7674A (pt)
MX (1) MXPA05001781A (pt)
NO (1) NO20050540L (pt)
OA (1) OA12894A (pt)
PA (1) PA8580401A1 (pt)
PE (1) PE20040866A1 (pt)
TN (1) TNSN05035A1 (pt)
TW (1) TW200407316A (pt)
UY (1) UY27928A1 (pt)
WO (1) WO2004014875A1 (pt)
ZA (1) ZA200500768B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (pt) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US6403587B1 (en) * 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
UA57824C2 (uk) * 1998-02-05 2003-07-15 Пфайзер Продактс Інк. Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
IL166548A0 (en) 2006-01-15
MXPA05001781A (es) 2005-04-25
JP2005538130A (ja) 2005-12-15
TNSN05035A1 (fr) 2007-05-14
OA12894A (en) 2006-10-13
EP1539715A1 (en) 2005-06-15
CA2494776A1 (en) 2004-02-19
US20040072834A1 (en) 2004-04-15
GT200300169A (es) 2004-05-12
IS7674A (is) 2005-01-27
PA8580401A1 (es) 2004-02-16
UY27928A1 (es) 2004-03-31
BR0313378A (pt) 2005-07-12
AU2003250450A1 (en) 2004-02-25
AP2005003226A0 (en) 2005-03-31
AR040839A1 (es) 2005-04-20
WO2004014875A1 (en) 2004-02-19
PE20040866A1 (es) 2004-11-26
ECSP055588A (es) 2005-04-18
NO20050540L (no) 2005-03-10
TW200407316A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
AU2003241561A1 (en) Pyrazolo-pyrimidine aniline compounds
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
ZA200409989B (en) Novel substituted sulfamate anticonvulsant derivatives.
AU2003282548A1 (en) Nano-chem-fet based biosensors
HK1072772A1 (en) Polymorph of acid 4-Ä2-Ä4-Ä1-(2-ethoxyethyl)-1H-benzimidazole-2-ilÜ-1-piperidinylÜethylÜ-alpha, alpha-dimethyl-benzeneacetic-4-Ä2-Ä4-Ä1-(2-
ZA200300208B (en) Manufacture of high octane alkylate.
AU2003255831A1 (en) Delayed-gelation solution
ZA200501624B (en) Flat lamp, production method thereof and application of same.
AU2003251779A1 (en) Electrode connector with rivet
ZA200500768B (en) Crystal forms os quinoxaline-2-carboxylic acid Ä4-carbomoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-,ethyl-octylÜ-amide
AU2003212979A1 (en) Substituted fused pyrazolecarboxylic acid arylamides and related compounds
AU2003225474A1 (en) Facilitating improved workflow
ITMI20022704A1 (it) Procedimento per la produzione di mesitilene e durene.
NO20023357D0 (no) Blanding
EP1582914A4 (en) DISPLAY ELEMENT, DISPLAY AND MANUFACTURING PROCESS FOR DISPLAY
DE60324703D1 (de) Barbitursäure derivaten.
IL163572A0 (en) Method for manufacturing flat paneldisplay substrates orbotech ltd.
AU2003225426A1 (en) Process for the preparation of urea
AU2003255454A1 (en) Heterocyclylcarbonyl aminocyclopropane carboxylic acid derivatives
AU2002950815A0 (en) Recovery nickel
AU2003252008A1 (en) High performance ortho upr
GB2389272B (en) SIM Configuration
AU2003301750A1 (en) Recovery process
AU2003272083A1 (en) Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
EP1587833A4 (en) EPAD, AN OOCYTE SPECIFIC PROTEIN